Inflammatory breast cancer
- PMID: 21310844
- DOI: 10.6004/jnccn.2011.0018
Inflammatory breast cancer
Abstract
Inflammatory breast cancer (IBC) represents the most virulent form of breast cancer, characterized by involvement of the skin and rapid progression of the disease. Management involves careful coordination of multidisciplinary modalities, including imaging, systemic chemotherapy, surgery, and radiation therapy. The use of neoadjuvant chemotherapy has contributed significantly to improvement in overall survival since the first descriptions of this entity, and has made the role of locoregional therapy, including surgery and radiation, critical to continued improvements in this disease. This article examines the unique epidemiology and pathology of IBC, and reviews the various treatment modalities, noting the significance of a multimodality approach and delineating each of the specific components. Moreover, the current research in IBC is briefly described, which experts hope will further improve systemic therapies.
Similar articles
-
Inflammatory breast cancer.Semin Radiat Oncol. 2009 Oct;19(4):256-65. doi: 10.1016/j.semradonc.2009.05.008. Semin Radiat Oncol. 2009. PMID: 19732690 Review.
-
Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy.Clin Breast Cancer. 2013 Oct;13(5):335-43. doi: 10.1016/j.clbc.2013.04.002. Epub 2013 Jul 10. Clin Breast Cancer. 2013. PMID: 23850216
-
Update on systemic treatment for newly diagnosed inflammatory breast cancer.J Adv Res. 2020 Aug 29;29:1-12. doi: 10.1016/j.jare.2020.08.014. eCollection 2021 Mar. J Adv Res. 2020. PMID: 33842000 Free PMC article. Review.
-
Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.Clin Breast Cancer. 2018 Aug;18(4):e501-e506. doi: 10.1016/j.clbc.2017.10.003. Epub 2017 Oct 7. Clin Breast Cancer. 2018. PMID: 29089281
-
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.Ann Oncol. 2011 Mar;22(3):515-523. doi: 10.1093/annonc/mdq345. Epub 2010 Jul 5. Ann Oncol. 2011. PMID: 20603440 Free PMC article.
Cited by
-
Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.Oncotarget. 2017 Jul 25;8(30):49370-49379. doi: 10.18632/oncotarget.17217. Oncotarget. 2017. PMID: 28472761 Free PMC article.
-
Reported breast symptoms in the National Breast and Cervical Cancer Early Detection Program.Cancer Causes Control. 2015 May;26(5):733-40. doi: 10.1007/s10552-015-0544-1. Epub 2015 Mar 10. Cancer Causes Control. 2015. PMID: 25754109 Free PMC article.
-
The Third International Inflammatory Breast Cancer Conference.Breast Cancer Res. 2013 Nov 5;15(6):318. doi: 10.1186/bcr3571. Breast Cancer Res. 2013. PMID: 24188125 Free PMC article.
-
1,25 Dihydroxyvitamin D3 uptake is localized at caveolae and requires caveolar function.J Biomed Nanotechnol. 2013 Oct;9(10):1707-15. doi: 10.1166/jbn.2013.1662. J Biomed Nanotechnol. 2013. PMID: 24015500 Free PMC article.
-
In Vitro Assessment of the Inflammatory Breast Cancer Cell Line SUM 149: Discovery of 2 Single Nucleotide Polymorphisms in the RNase L Gene.J Cancer. 2013;4(2):104-16. doi: 10.7150/jca.5002. Epub 2013 Jan 10. J Cancer. 2013. PMID: 23386909 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
